Stockscreener 앱 받기
145.12
0.19%
0.25
전일 마감가:
$144.87
열려 있는:
$146.3
하루 거래량:
872.03K
Relative Volume:
0.61
시가총액:
$21.27B
수익:
$9.61B
순이익/손실:
$1.53B
주가수익비율:
13.87
EPS:
10.46
순현금흐름:
$1.85B
1주 성능:
-2.48%
1개월 성능:
+6.80%
6개월 성능:
+1.44%
1년 성능:
-26.54%
1일 변동 폭
$143.37
$146.45
1주일 범위
$141.12
$150.28
52주 변동 폭
$110.03
$204.18
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
BIIB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
145.07 | 21.24B | 9.61B | 1.53B | 1.85B | 10.46 |
|
LLY
Lilly Eli Co
|
759.60 | 681.42B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
174.97 | 426.76B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
221.81 | 390.07B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
122.72 | 237.08B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
NVO
Novo Nordisk Adr
|
61.59 | 258.61B | 45.44B | 16.18B | 9.21B | 3.634 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-21 | 재개 | Truist | Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-04-04 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-11 | 개시 | Bernstein | Mkt Perform |
| 2025-01-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen (BIIB) to Acquire Alcyone Therapeutics for $85M - GuruFocus
December 19th Options Now Available For Biogen (BIIB) - Nasdaq
Biogen acquires Lowell firm developing device meant replace the spinal tap - The Business Journals
Biogen to acquire Alcyone Therapeutics - The Pharma Letter
Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs - BioPharma Dive
Biogen Inc. entered into a definitive agreement to acquire All Assets of Alcyone Therapeutics, Inc. for $85 million. - MarketScreener
Biogen Gets EU Nod for First Postpartum Depression Drug - Yahoo Finance
Biogen to buy Massachusetts-based Alcyone Therapeutics (BIIB:NASDAQ) - Seeking Alpha
Biogen To Acquire Alcyone Therapeutics - Nasdaq
Biogen to Acquire Alcyone Therapeutics for Initial $85 million - MarketScreener
Biogen (BIIB) to Acquire Alcyone Therapeutics for Innovative Dru - GuruFocus
Biogen to acquire Alcyone Therapeutics for $85 million - Investing.com
Biogen to buy Alcyone Therapeutics, expanding drug delivery solutions for key products and pipeline - MarketScreener
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates - Biogen
Biogen’s Zurzuvae approved as first postpartum depression drug in Europe - Yahoo Finance
EC nod for Biogen’s PPD drug Zurzuvae - The Pharma Letter
EC approves Biogen’s ZURZUVAE as first oral treatment for postpartum depression - Investing.com Australia
MBB Public Markets I LLC Acquires Shares of 2,150 Biogen Inc. $BIIB - MarketBeat
34,000 Shares in Biogen Inc. $BIIB Purchased by Strs Ohio - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Sells 23,427 Shares of Biogen Inc. $BIIB - MarketBeat
Jacobi Capital Management LLC Acquires 2,064 Shares of Biogen Inc. $BIIB - MarketBeat
Swedbank AB Has $29.84 Million Holdings in Biogen Inc. $BIIB - MarketBeat
Pullback Watch: Can Biogen Inc. sustain its profitability2025 Technical Patterns & Daily Oversold Stock Bounce Ideas - خودرو بانک
Aug PostEarnings: Can Biogen Inc outperform in the next rally2025 Major Catalysts & Precise Swing Trade Entry Alerts - خودرو بانک
Biogen (BIIB) Gains EU Approval for Post-Partum Depression Treat - GuruFocus
Biogen (BIIB) Receives E.U. Approval for ZURZUVAE in Treating Po - GuruFocus
Biogen receives European Commission approval for Zurzuvae - MarketScreener
Biogen gets EU nod for Zurzuvae to treat post-partum depression - MSN
Biogen Receives European Commission Approval for ZURZUVAE® to Treat Postpartum Depression - Quiver Quantitative
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe - Biogen
First-Ever Oral Postpartum Depression Treatment: Biogen's ZURZUVAE Gets EU Green Light for 14-Day Therapy - Stock Titan
Biogen (BIIB) Receives a Hold from J.P. Morgan - The Globe and Mail
Biogen Inc. $BIIB Shares Acquired by Woodline Partners LP - MarketBeat
United Services Automobile Association Purchases Shares of 3,604 Biogen Inc. $BIIB - MarketBeat
Voya Investment Management LLC Reduces Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Acadian Asset Management LLC Purchases 14,357 Shares of Biogen Inc. $BIIB - MarketBeat
Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way - Yahoo Finance
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Biogen Inc 주식 (BIIB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
1.34%
자본화:
|
볼륨(24시간):